Vida Ventures - Company Profile

Jan. 7 Quick Takes: Strong demand for Cullinan IPO; plus Bayer-CureVac COVID deal and venture rounds for Scorpion, Kira, Carisma and Abcuro and more

...series B round led by Boxer Capital of Tavistock Group, EcoR1 Capital, Omega Funds and Vida Ventures...
...ErbB2; neu) – Epidermal growth factor receptor 2 BC Staff CVnCoV CT-0508 (CARMA-0508) ARGX-113 (efgartigimod) Bayer AG CureVac N.V. Boxer Capital EcoR1 Capital Omega Funds Vida Ventures Surveyor...

Kite, Forty Seven vets on board for launch of oncolytic virus start-up IconOVir with $77M series A

...Inc. (NASDAQ:GILD); venture investor Jakob Loven of Nextech; and former Kite CSO David Chang.Nextech and Vida Ventures...
...a scientific co-founderAcademic collaborators: Salk InstituteCorporate partners: NoneNumber of employees: 10Funds raised: $77 millionInvestors: Nextech, Vida Ventures...

Dec. 14 Quick Takes: Locanabio raises $100M series B; plus rare bleeding disorder newco Hemab, raises for Rani, CG, InnoSkel, Denovo, Biosion and more

...leads Locanabio’s $100M B roundLocanabio Inc. raised $100 million in a series B financing led by Vida Ventures...
...third investment in four months for the new Paris-based VC and its second investing alongside Vida Ventures...
...shareholders, including the Elliott Advisors Ltd. affiliate of Elliott Management Corp. TARGETSTSLP – Thymic stromal lymphopoietin BC Staff CG0070 HTD1801 Locanabio Inc. Vida Ventures RA...

...collaborators: NoneCorporate partners: Innovative Targeting SolutionsNumber of employees: 50Funds raised: $136 millionInvestors: The Column Group, Vida Ventures...

Cell therapy play Neogene’s $110M series A marks first investment for Tordjman’s Jeito Capital

...Syncona Ltd. (LSE:SYNC) with participation from Polaris Partners and Pontifax as well as seed investors Vida Ventures...
...Therapeutics Ltd., which is developing macrophage therapies for end-stage renal disease. Karen Tkach Tuzman Neogene Therapeutics Inc. Syncona Ltd. Vida Ventures Pact...

BioCentury | Jan 9, 2021

Finance

Closing year with flurry of deals, Tordjman’s Jeito fine-tunes its investment strategy

...four months and its second investing alongside Vida Ventures, whose...

BioCentury | Jan 8, 2021

Deals

Jan. 7 Quick Takes: Strong demand for Cullinan IPO; plus Bayer-CureVac COVID deal and venture rounds for Scorpion, Kira, Carisma and Abcuro and more

BioCentury | Jan 6, 2021

Emerging Company Profile

Kite, Forty Seven vets on board for launch of oncolytic virus start-up IconOVir with $77M series A

BioCentury | Dec 15, 2020

Finance

Dec. 14 Quick Takes: Locanabio raises $100M series B; plus rare bleeding disorder newco Hemab, raises for Rani, CG, InnoSkel, Denovo, Biosion and more

BioCentury | Oct 29, 2020

Finance

Perceptive-backed in-licensing play LianBio to cast a wide net with $310M crossover round

...T. Rowe Price Associates, Tybourne Capital Management, Vida Ventures...

BioCentury | Oct 26, 2020

Deals

Bayer’s $2B deal for AskBio follows biotech’s decision to bet on its own pipeline

...raised $225 million from TPG Capital and Vida Ventures...

BioCentury | Oct 26, 2020

Emerging Company Profile

Serial dealmaker Glick to lead cancer start-up Scorpion with familiar VCs supplying $108M

...or its asset-focused descendants. Atlas, Omega and Vida Ventures...
...raised: $108 millionInvestors: Atlas Venture, Omega Funds, Vida Ventures...

BioCentury | Oct 9, 2020

Emerging Company Profile

A2: targeting lost genetic material to distinguish tumors from normal cells

...collaborators: NoneCorporate partners: Innovative Targeting SolutionsNumber of employees: 50Funds raised: $136 millionInvestors: The Column Group, Vida Ventures...

BioCentury | Sep 15, 2020

Finance

Cell therapy play Neogene’s $110M series A marks first investment for Tordjman’s Jeito Capital

BioCentury | Aug 25, 2020

Finance

$155M Perceptive-led note deal enables Kronos to fund newly acquired Gilead asset’s pivotal trial

...Kronos raised $105 million in a July 2019 series A round led by seed investors Vida Ventures...

Closing year with flurry of deals, Tordjman’s Jeito fine-tunes its investment strategy

Jan. 7 Quick Takes: Strong demand for Cullinan IPO; plus Bayer-CureVac COVID deal and venture rounds for Scorpion, Kira, Carisma and Abcuro and more

Kite, Forty Seven vets on board for launch of oncolytic virus start-up IconOVir with $77M series A

Dec. 14 Quick Takes: Locanabio raises $100M series B; plus rare bleeding disorder newco Hemab, raises for Rani, CG, InnoSkel, Denovo, Biosion and more

Perceptive-backed in-licensing play LianBio to cast a wide net with $310M crossover round

Bayer’s $2B deal for AskBio follows biotech’s decision to bet on its own pipeline

Serial dealmaker Glick to lead cancer start-up Scorpion with familiar VCs supplying $108M

A2: targeting lost genetic material to distinguish tumors from normal cells

Cell therapy play Neogene’s $110M series A marks first investment for Tordjman’s Jeito Capital

$155M Perceptive-led note deal enables Kronos to fund newly acquired Gilead asset’s pivotal trial

Closing year with flurry of deals, Tordjman’s Jeito fine-tunes its investment strategy

Jan. 7 Quick Takes: Strong demand for Cullinan IPO; plus Bayer-CureVac COVID deal and venture rounds for Scorpion, Kira, Carisma and Abcuro and more

Kite, Forty Seven vets on board for launch of oncolytic virus start-up IconOVir with $77M series A

Dec. 14 Quick Takes: Locanabio raises $100M series B; plus rare bleeding disorder newco Hemab, raises for Rani, CG, InnoSkel, Denovo, Biosion and more

Perceptive-backed in-licensing play LianBio to cast a wide net with $310M crossover round

Bayer’s $2B deal for AskBio follows biotech’s decision to bet on its own pipeline

Serial dealmaker Glick to lead cancer start-up Scorpion with familiar VCs supplying $108M

A2: targeting lost genetic material to distinguish tumors from normal cells

Cell therapy play Neogene’s $110M series A marks first investment for Tordjman’s Jeito Capital

$155M Perceptive-led note deal enables Kronos to fund newly acquired Gilead asset’s pivotal trial

Products & Solutions

About Biocentury

Contact

Privacy & Legal